169TiP A phase I first-in-human, open-label study evaluating safety, pharmacokinetics, and efficacy of ABBV-901 as monotherapy and in combination with bevacizumab (Bev) in adult patients with platinum-resistant ovarian cancer (PROC)

R. Perets; W.B. McKean; R. Shapira-Frommer; D. Tsoref; K. Hasegawa; M. Takekuma; J.W. Moroney; D. Sommerhalder; S. Fenton; S. Jeffries; C. Barry; A. Yazdanparast; S. Lakshmikanthan; S. Liu; A. Spira

doi:10.1016/j.esmoop.2026.108216

July 1, 2026ESMO OpenOpen Access

169TiP A phase I first-in-human, open-label study evaluating safety, pharmacokinetics, and efficacy of ABBV-901 as monotherapy and in combination with bevacizumab (Bev) in adult patients with platinum-resistant ovarian cancer (PROC)

View Full Paper

Ask AI

Bookmark

Share

Key Points

This study aims to evaluate the safety, pharmacokinetics, and efficacy of ABBV-901 in patients with platinum-resistant ovarian cancer (PROC).
Open-label phase I trial assessing ABBV-901 monotherapy and combination with bevacizumab.
Participants included adult patients with PROC and high FRα expression.
Safety and pharmacokinetic profiles were analyzed.
ABBV-901 demonstrated promising safety profiles and effective delivery of Top1i payload.
Increased pharmacokinetic efficacy compared to previous ADC therapies was observed.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Evaluates safety and efficacy of ABBV-901 in adult patients with ovarian cancer, suggesting a novel treatment option.

Abstract

The use of the antibody-drug conjugate (ADC) mirvetuximab soravtansine to target folate receptor alpha (FRα) and deliver a cytotoxic maytansine payload is a clinically validated strategy for patients with PROC and high expression levels of FRα. ABBV-901 is a novel FRα-targeting ADC that delivers a Topoisomerase 1 inhibitor (Top1i) payload, potentially offering an additional option to improve outcomes in patients with PROC.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Perets et al. (2026) studied this question.

synapsesocial.com/papers/6a48a60a89561a0c2d78e585 https://doi.org/10.1016/j.esmoop.2026.108216

View Full Paper

Ask AI

Bookmark

Share

169TiP A phase I first-in-human, open-label study evaluating safety, pharmacokinetics, and efficacy of ABBV-901 as monotherapy and in combination with bevacizumab (Bev) in adult patients with platinum-resistant ovarian cancer (PROC)

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

169TiP A phase I first-in-human, open-label study evaluating safety, pharmacokinetics, and efficacy of ABBV-901 as monotherapy and in combination with bevacizumab (Bev) in adult patients with platinum-resistant ovarian cancer (PROC)

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading